Regulus Therapeutics Inc. (RGLS) has 56 open-market insider trades by 31 insiders since 2012. The most active filer is Stelios Papadopoulos, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Ab Astrazeneca | 10% | — | 1 | $34.0M | 2014-11-12 |
| Pharmaceuticals Inc Isis | 10% | — | 4 | $27.2M | 2015-07-17 |
| Sanofi | 10% | — | 1 | $10.0M | 2014-02-04 |
| Scott D. Sandell | 10% Owner | — | 2 | $7.9M | 2020-12-04 |
| Forest Baskett | 10% Owner | — | 2 | $7.9M | 2020-12-04 |
| Joshua Makower | 10% Owner | — | 2 | $7.9M | 2020-12-04 |
| Mohamad Makhzoumi | 10% Owner | — | 2 | $7.9M | 2020-12-04 |
| Paul Edward Walker | 10% Owner | — | 2 | $7.9M | 2020-12-04 |
| Carmen Chang | 10% Owner | — | 2 | $7.9M | 2020-12-04 |
| Anthony A. Florence Jr. | 10% Owner | — | 2 | $7.9M | 2020-12-04 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Preston Klassen | President | Buy | $96K | 2025-06-03 |
| Joseph P. Hagan | CEO | Buy | $109K | 2025-01-30 |
| David Baltimore | Director | Buy | $21K | 2025-01-30 |
| Joseph P. Hagan | CEO | Sell | $305K | 2025-01-13 |
| Preston Klassen | President | Sell | $40K | 2025-01-13 |
| Christopher Ray Aker | Sr. VP & General Counsel | Sell | $55K | 2025-01-13 |
Companies that share insiders with RGLS, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Crispina Calsada | CFO | Sell | $55K | 2025-01-13 |
| Kathryn J. Collier | Director | Buy | $7K | 2024-07-25 |
| Christopher Ray Aker | Sr. VP & General Counsel | Sell | $7K | 2024-01-18 |
| Joseph P. Hagan | CEO | Sell | $17K | 2024-01-18 |
| Denis Drygin | Chief Scientific Officer | Buy | $18K | 2022-03-01 |
| Denis Drygin | Chief Scientific Officer | Buy | $5K | 2022-02-04 |
| Joseph P. Hagan | President | Buy | $22K | 2022-01-26 |
| Joseph P. Hagan | President | Sell | $4K | 2021-05-17 |
| Christopher Ray Aker | Sr. VP & General Counsel | Sell | $765 | 2021-05-17 |